Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
New polymorphs of Eltrombopag and Eltrombopag ethanolamine salt have been obtained and characterized. These polymorphs and pharmaceutical compositions comprising them are useful, for example, in treating conditions leading to thrombocytopenia.
1. Crystalline Eltrombopag.
2. The crystalline Eltrombopag according to claim 1 , wherein the crystalline Eltrombopag is selected from the group consisting of:
crystalline Eltrombopag Form I characterized by data selected from the group consisting of: a powder XRD pattern having peaks at 4.0, 7.3, 7,7, 12.1 and 16.1° 2θ±0.2° 2θ; a PXRD pattern as depicted in FIG. 1 ; and any combination thereof;
crystalline Eltrombopag form III characterized by data selected from the group consisting of: a powder XRD pattern having peaks at 9.2, 11.2, 12.2 and 14.0° 2θ±0.2° 2θ; a PXRD pattern as depicted in FIG. 3 ; and any combination thereof;
crystalline Eltrombopag Form IV characterized by data selected from the group consisting of: a powder XRD pattern having peaks at 5.5, 9.6, 14.5, 16.5 and 19.3° 2θ±0.2° 2θ; a PXRD pattern as depicted in FIG. 5 ; and any combination thereof;
crystalline Eltrombopag Form V characterized by data selected from the group consisting of: a powder XRD pattern having peaks at 5.9, 8,2, 10.5 and 12.5° 2θ±0.2° 2θ; a PXRD pattern as depicted in FIG. 7 ; and any combination thereof;
crystalline Eltrombopag form VI characterized by data selected from the group consisting of: a powder XRD pattern having peaks at 5.9, 8.8, 10.3 and 11.7° 2θ±0.2° 2θ; a PXRD pattern as depicted in FIG. 9 ; and any combination thereof;
crystalline Eltrombopag Form VII characterized by data selected from the group consisting of: a powder XRD pattern having peaks at 7.6, 9.4, 15.0 and 16.0° 2θ±0.2° 2θ; a PXRD pattern as depicted in FIG. 10 ; and any combination thereof;
crystalline Eltrombopag Form VIII characterized by data selected from the group consisting of: a powder XRD pattern having peaks at 9.0, 13.2, 16,0 and 24.0° 2θ±0.2° 2θ; a PXRD pattern as depicted in FIG. 11 ; and any combination thereof;
crystalline Eltrombopag Form IX characterized by a data selected from a group consisting of: a powder XRD pattern having peaks at 4.5, 14.2, 17.4 and 18.0° 2θ±0.2° 2θ; a PXRD pattern as depicted in FIG. 13 ; and any combination thereof;
crystalline Eltrombopag form X characterized by a data selected from a group consisting of: a powder XRD pattern haying peaks at 6.9, 13.8, 20.4 and 24.7° 2θ±0.2° 2θ; a PXRD pattern as depicted in FIG. 14 ; and any combination thereof;
crystalline Eltrombopag form XI characterized by a data selected from a group consisting of: a powder XRD pattern haying peaks at 3.5, 10.5, 14.0 and 28.4° 2θ±0.2° 2θ; a PXRD pattern as depicted in FIG. 15 ; and any combination thereof;
crystalline Eltrombopag form XII characterized by a data selected from a group consisting of: a powder XRD pattern having peaks at 4.6, 7.6, 8.9 and 16.2° 2θ±0.2° 2θ; a PXRD pattern as depicted in FIG. 16 ; and any combination thereof;
crystalline Eltrombopag form XIII characterized by a data selected from a group consisting of a powder XRD pattern having peaks at 3.9, 7.8, 11.7 and 12.4° 2θ±0.2° 2θ; a PXRD pattern as depicted in FIG. 17 ; and any combination thereof;
crystalline Eltrombopag form XIV characterized by a data selected from a group consisting of a powder XRD pattern haying peaks at 5.0, 10.7, 19.0 and 21.4° 2θ±0.2° 2θ; a PXRD pattern as depicted in FIG. 18 ; and any combination thereof;
crystalline Eltrombopag form XV characterized by a data selected from a group consisting of: a powder XRD pattern having peaks at 11.5, 12.0, 12.5 and 20.9° 2θ±0.2° 2θ; a PXRD pattern as depicted in FIG. 19 ; and any combination thereof;
crystalline Eltrombopag form XVI characterized by a data selected from a group consisting of: a powder XRD pattern having peaks at 7.1 , 9.5, 13.9, 21.2 and 25.5° 2θ±0.2° 2θ; a PXRD pattern as depicted in FIG. 20 ; and any combination thereof; and mixtures thereof.
3. A pharmaceutical composition comprising crystalline Eltrombopag and at least one pharmaceutically acceptable excipient.
4. A process for preparing Eltrombopag monoethanolamine salt comprising preparing a crystalline Eltrombopag according to claim 1 and reacting the crystalline Eltrombopag with ethanolamine to obtain Eltrombopag monoethanolamine salt.
5. A process for preparing Eltrombopag monoethanolamine salt comprising preparing a crystalline Eltrombopag according to claim 2 and reacting the crystalline Eltrombopag with ethanolamine to obtain Eltrombopag monoethanolamine salt.
6. A process for preparing Eltrombopag bisethanolamine salt comprising preparing a crystalline Eltrombopag according to claim 1 and reacting the crystalline Eltrombopag with ethanolamine to obtain Eltrombopag bisethanolamine salt.
7. A process for preparing Eltrombopag bisethanolamine salt comprising preparing a crystalline Eltrombopag according to claim 2 and reacting the crystalline Eltrombopag with ethanolamine to obtain Eltrombopag bisethanolamine salt.
8. The process according to claim 4 , wherein the Eltrombopag monoethanolamine salt has a chemical purity of at least 99%.
9. The process according to claim 5 , wherein the Eltrombopag bisethanolamine salt has a chemical purity of at least 99%.